<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Anaesthesiol Intensive Ther</journal-id><journal-id journal-id-type="iso-abbrev">Anaesthesiol Intensive Ther</journal-id><journal-id journal-id-type="pmc-domain-id">4356</journal-id><journal-id journal-id-type="pmc-domain">ait</journal-id><journal-id journal-id-type="publisher-id">AIT</journal-id><journal-title-group><journal-title>Anaesthesiology Intensive Therapy</journal-title></journal-title-group><issn pub-type="ppub">1642-5758</issn><issn pub-type="epub">1731-2531</issn><publisher><publisher-name>Polish Society of Anaesthesiology and Intensive Therapy</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10156511</article-id><article-id pub-id-type="pmcid-ver">PMC10156511.1</article-id><article-id pub-id-type="pmcaid">10156511</article-id><article-id pub-id-type="pmcaiid">10156511</article-id><article-id pub-id-type="pmid">36062420</article-id><article-id pub-id-type="doi">10.5114/ait.2022.118881</article-id><article-id pub-id-type="publisher-id">47669</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review Articles</subject></subj-group></article-categories><title-group><article-title>Are we ready to manage an opioid epidemic in the intensive care unit?</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Das</surname><given-names initials="AK">Akshaya K.</given-names></name></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Sharma</surname><given-names initials="A">Ankur</given-names></name><xref rid="cor1" ref-type="corresp"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kothari</surname><given-names initials="N">Nikhil</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Goyal</surname><given-names initials="S">Shilpa</given-names></name></contrib></contrib-group><aff id="aff1">All India Institute of Medical Sciences, Jodhpur, India</aff><author-notes><corresp id="cor1"><bold>CORRESPONDING AUTHOR:</bold> Dr. Ankur Sharma, All India Institute of Medical Sciences, Jodhpur, India, e-mail: <email>ankuranaesthesia@gmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>02</day><month>9</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>54</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">434937</issue-id><fpage>271</fpage><lpage>278</lpage><history><date date-type="received"><day>22</day><month>10</month><year>2021</year></date><date date-type="accepted"><day>18</day><month>5</month><year>2022</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>17</day><month>05</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-17 00:25:25.503"><day>17</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; Polish Society of Anaesthesiology and Intensive Therapy</copyright-statement><copyright-year>2022</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncsalicense">https://creativecommons.org/licenses/by-nc-sa/4.0/</ali:license_ref><license-p>This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-sa/4.0/">http://creativecommons.org/licenses/by-nc-sa/4.0/</ext-link>), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="AIT-54-47669.pdf"/><abstract><p>The current opioid epidemic has had a massive impact on the critical care sector. This is due to an increase in the number of acute opioid overdose-related admissions and the number of opioid-dependent and opioid-tolerant patients admitted to intensive care units (ICUs). This review discusses the challenges that intensive care physicians face when caring for patients suffering from opioid-related disorders and analyses existing solutions. Preference for non-opioid analgesics, treatment of acute pain in the ICUs to avoid chronic pain syndrome, and education of patients and caregivers are critical to preventing this pandemic.</p></abstract><kwd-group><kwd>opioid crisis</kwd><kwd>opioid withdrawal</kwd><kwd>chronic ICU pain</kwd><kwd>COVID-19 pandemic</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>The opioid epidemic began with the over-prescription of opioids for palliative care and pain practices, as pain was considered the 5<sup>th</sup> vital sign by the internal Association for the Study of Pain in 1990 [<xref rid="ref1" ref-type="bibr">1</xref>]. Overdose deaths have been historically described in three waves, with the first wave starting in the early 1990s with the over-prescription of natural and semisynthetic opioids and methadone [<xref rid="ref2" ref-type="bibr">2</xref>]. the second wave in 2010 and the third wave in 2013 were due to the overdose of heroin and illicitly manufactured fentanyl [<xref rid="ref3" ref-type="bibr">3</xref>&#8211;<xref rid="ref6" ref-type="bibr">6</xref>]. More recently, there have been increased reports of the use of illicitly manufactured fentanyl, fentanyl-related substances, and other opioid-related substances (i.e., U-47700) either alone or in combination with heroin [<xref rid="ref7" ref-type="bibr">7</xref>&#8211;<xref rid="ref14" ref-type="bibr">14</xref>].</p><p>The opioid epidemic contributes to the deaths related to opioid overdose or misuse and weakens a country&#8217;s economy. According to a systematic review including six studies with 810 patients who underwent different surgical procedures, postoperative opioids often remain unused and undisposed [<xref rid="ref15" ref-type="bibr">15</xref>]. this overprescribed, unused drug is considered a source for the dispersion of opioids in the community and is a new contributing factor to the current opioid epidemic [<xref rid="ref16" ref-type="bibr">16</xref>].</p><sec id="S1"><title>THE OPIOID EPIDEMIC IN THE INTENSIVE CARE UNIT</title><p>Intensive care units (ICUs) have witnessed a rise in opioid-related overdoses, with admissions for overdoses increasing by 34% between 2009 and 2015. Furthermore, the mortality rate of critically ill patients hospitalised for overdose rose from 7.3% to 9.8% during the same period [<xref rid="ref17" ref-type="bibr">17</xref>]. there is undoubtedly a need for critical care practitioners to be aware of opioid use disorders since there are an increasing number of patients who receive opioids in the ICU environment. in one study, almost 80% of patients on mechanical ventilation were administered opioids, and this figure increased to over 90% for patients on mechanical ventilation for more than seven days [<xref rid="ref18" ref-type="bibr">18</xref>]. Additionally, these hospitalisations might result in increased hospital and societal expenses since this group may need an increasing amount of sophisticated and costly multi-organ support. Stevens <italic toggle="yes">et al</italic>. [<xref rid="ref17" ref-type="bibr">17</xref>] estimated a nearly 60% increase in the cost of each opioid overdose ICU hospitalisation, demonstrating the strain on the healthcare system caused by the opioid crisis.</p><p>Different reports have shown a sharp rise in morbidity and mortality from opioid overdose and misuse during the coronavirus disease 2019 (COVID-19) pandemic [<xref rid="ref19" ref-type="bibr">19</xref>]. A recent report has shown that the number of cases of opioid overdoses increased in Kentucky during the early weeks of the COVID-19 pandemic [<xref rid="ref20" ref-type="bibr">20</xref>]. Deaths due to synthetic opioids increased 38.4% in the 12 months ending in June 2019 compared with the 12 months ending in May 2020, which made the opioid epidemic worsen [<xref rid="ref21" ref-type="bibr">21</xref>]. there was a 35% increase in test positivity for non-prescribed fentanyl and a 44% increase for heroin during the COVID-19 pandemic [<xref rid="ref22" ref-type="bibr">22</xref>]. the sharp rise in medical issues related to opioid misuse is related to the unavailability of opioids for chronic pain management, financial insecurity, and loss of jobs [<xref rid="ref23" ref-type="bibr">23</xref>]. Restrictive opioid-prescribing early in the COVID-19 pandemic can lead to reflex over-prescribing later to avoid frequent wasteful visits for refills, and reflex over-prescribing also occurs due to an over-correction for earlier under-prescribing [<xref rid="ref24" ref-type="bibr">24</xref>]. in the early COVID-19 pandemic, the availability of opioids was slightly hampered among the patients dependent on opioid analgesics, but later, clinicians adjusted the prescription to include larger quantities [<xref rid="ref25" ref-type="bibr">25</xref>]. while COVID-19 imposed several significant barriers to treatment for these people, it was also accompanied by changes that improved access to care. these measures include lowering financial obstacles to treatment via an emergency Medicaid expansion and increasing the use of telemedicine in the care of people with opioid use disorder [<xref rid="ref26" ref-type="bibr">26</xref>]. the guidance released by the Substance Abuse and Mental Health Services Administration (SAMHSA) during the COVID-19 pandemic had a potential risk of non-medical use of methadone in a patient with an opioid use disorder [<xref rid="ref27" ref-type="bibr">27</xref>]. to address this issue, patients receiving take-home methadone should be co-prescribed naloxone, which may lower the risk of lethal overdose.</p><p>Patients with COVID-19 pneumonia and a preexisting opioid abuse disorder have increased mortality and morbidity. Patients with opioid use disorder have increased odds of hospitalisation, length of stay, and invasive ventilation requirements due to COVID-19 [<xref rid="ref28" ref-type="bibr">28</xref>]. the cDc recommended expanding naloxone distribution, awareness about substance use disorders, early detection, and intervention to combat the crisis [<xref rid="ref29" ref-type="bibr">29</xref>].</p><p>India is sandwiched between major opium- producing countries such as Afghanistan, Myanmar, and thailand. Apart from that, india is becoming a central production hub for opium for the legal pharmaceutical market. Synthetic opioids have been out of reach for the general population due to restrictions placed by the government of india [<xref rid="ref30" ref-type="bibr">30</xref>&#8211;<xref rid="ref32" ref-type="bibr">32</xref>]. india has the second-highest population globally, but the irony is that less than 1% of people receive pain management and palliative care services [<xref rid="ref33" ref-type="bibr">33</xref>]. Many patients suffering from chronic pain due to cancer are out of reach of adequate opioid analgesics.</p><p>In contrast, there is a parallel increase in the prevalence of heroin addiction in some parts of india [<xref rid="ref34" ref-type="bibr">34</xref>]. According to different survey reports, it is clear that drug abuse in india has increased [<xref rid="ref35" ref-type="bibr">35</xref>, <xref rid="ref36" ref-type="bibr">36</xref>]. india&#8217;s three major poppy-growing states are Rajasthan, Madhya Pradesh, and Rajasthan. According to an observational study conducted in 45 rural villages of Rajasthan province of india&#8217;s Barmer, Jaisalmer, and Bikaner districts, the addiction rate was 8.4%, 79%, and 6.9%, respectively [<xref rid="ref37" ref-type="bibr">37</xref>]. Malviya <italic toggle="yes">et al</italic>. [<xref rid="ref38" ref-type="bibr">38</xref>] conducted a prospective cohort study from December 2004 to February 2006 in a tertiary hospital in western Rajasthan; they found a higher incidence of postoperative respiratory, cardiovascular, systemic, and local complications associated with patients with opioid use disorders.</p><p>Although not labelled as an opioid epidemic like in the United States, there is a possibility of a significant impact of opioid use on general health due to an amendment to the Narcotic Drugs and Psychotropic Substances (NDPS) Act in 2014 [<xref rid="ref39" ref-type="bibr">39</xref>]. this law prevents illicit opioids while promoting the medical and scientific use of essential opioids. Due to the need for multiple licenses, state permissions, and complexities, opioids are less accessible for general use, exacerbating the opioid crisis. in many states of india, there is an increased report of drug trafficking and opioid-associated medical issues among young adults [<xref rid="ref40" ref-type="bibr">40</xref>&#8211;<xref rid="ref43" ref-type="bibr">43</xref>]. Opium use has been integrated into social customs in some parts of the country and has become a social, mental, and economic burden [<xref rid="ref44" ref-type="bibr">44</xref>, <xref rid="ref45" ref-type="bibr">45</xref>]. this opioid use disorder led to hospitalisation for intoxication and issues related to opioid withdrawal [<xref rid="ref46" ref-type="bibr">46</xref>].</p></sec><sec id="S2"><title>OPIOID ADDICTION DISORDERS</title><p>According to DSM-5, the criteria for opioid use disorder include the presence of at least 2 out of the following 11 criteria [<xref rid="ref47" ref-type="bibr">47</xref>]:
<list list-type="bullet"><list-item><p>consumption of opioids in larger amounts and for a longer period;</p></list-item><list-item><p>persistent desire to control opioid use, the strong desire to take opioid;</p></list-item><list-item><p>much more time is spent to obtain opioids, use them and recover from their effects;</p></list-item><list-item><p>strong urge to use opioids;</p></list-item><list-item><p>failure to complete major role obligations at the workplace;</p></list-item><list-item><p>continued opioid use despite persistent social issues caused by the effects of opioids;</p></list-item><list-item><p>reduced social, occupational, and recreational activities;</p></list-item><list-item><p>recurrent opioid use in a physically hazardous situation;</p></list-item><list-item><p>continued opioid use despite knowing its recurrent physical and psychological hazards;</p></list-item><list-item><p>opioid tolerance;</p></list-item><list-item><p>withdrawal symptoms.</p></list-item></list></p><p>The severity of opioid use disorder can be graded based on the number of symptoms/criteria present (mild = 2&#8211;3, moderate = 4&#8211;5, severe = 6 or more).</p><p>A patient with an opioid use disorder can present in various forms in the ICU. these can include the following types of problems and complications faced by intensivists during patient management:
<list list-type="bullet"><list-item><p>acute, life-threatening intoxication;</p></list-item><list-item><p>the opioid-addicted patient presents with a critical illness;</p></list-item><list-item><p>opioid withdrawal (including iatrogenic) in the critical care setting;</p></list-item><list-item><p>perioperative management of patients with opioid addiction or chronic opioid use for medical purposes;</p></list-item><list-item><p>pain management for acute or chronic illnesses;</p></list-item><list-item><p>complications due to chronic opioid use are similar to those from other drug abuse, such as the risk of Hiv and other infections and skin infections;</p></list-item><list-item><p>chronic intensive care related to pain.</p></list-item></list></p><p>Managing a patient with an opioid use disorder can be extremely difficult for a health care provider. the challenge for an intensivist starts with the patient with an acute life-threatening overdose of opioids in an emergency and lasts until discharge and rehabilitation therapy. According to one study, opioid overdose is associated with simultaneous consumption of other agents such as alcohol, marijuana, lysergic acid diethylamide (LSD), amphe tamine, benzodiazepines, and cocaine [<xref rid="ref48" ref-type="bibr">48</xref>]. concurrent use of various illicit substances further complicates the management of these patients.</p></sec><sec id="S3"><title>THE ROLE OF THE INTENSIVIST IN COMBATING THE OPIOID EPIDEMIC</title><p>According to a recent report from the world Health Organization (WHO), 0.5 million deaths are due to drug abuse, with 70% involving opioids and 30% of deaths due to overdose [<xref rid="ref49" ref-type="bibr">49</xref>]. Opioid-related deaths in 2019 quadrupled compared to 1999 [<xref rid="ref50" ref-type="bibr">50</xref>]. the COVID-19 pandemic has accelerated the rate of death associated with synthetic opioids in the USA [<xref rid="ref51" ref-type="bibr">51</xref>]. the United States Department of Health and Human Services initiated a 5-point strategy to combat the opioid epidemic, including better addiction prevention and recovery services, data collection, research, pain management, and the availability of overdose-reversing drugs [<xref rid="ref52" ref-type="bibr">52</xref>].</p><p>Pain is considered the fifth vital sign, and adequate analgesia in ICU patients is one of the prime areas of concern. Acute pain is often undertreated in opioid-dependent patients admitted to the intensive care unit. Postsurgical pain, immobility, indwelling devices, and procedures during an ICU stay such as chest tube removal, wound drain removal, and arterial line insertion can contribute to acute pain in these patients [<xref rid="ref53" ref-type="bibr">53</xref>]. Failure to manage acute pain can lead to agitation, sympathetic overactivity, neurobehavioral changes, and progression to chronic pain in ICU patients [<xref rid="ref54" ref-type="bibr">54</xref>]. Opioids are the mainstay treatment for acute pain in the ICU. Patients with opioid addiction should maintain their pre-existing opioid agonist treatment, supplemented with short-acting analgesics as required for acute pain. when prescribing opioids to patients, the intensivist should be cautious regarding the history of opioid addiction as well as the potential risk of opioid tolerance, dependence, and addiction among ICU survivors (<xref rid="F1" ref-type="fig">Figure 1</xref>). Among ICU survivors, opioid prescribing is higher in postsurgical patients than in medical patients [<xref rid="ref55" ref-type="bibr">55</xref>].</p><fig position="float" id="F1" orientation="portrait"><label>FIGURE 1</label><caption><p>Role of intensivist to combat the opioid epidemic</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="AIT-54-47669-g001.jpg"/></fig><p>One of the adverse effects of chronic pain therapy is opioid misuse, hampering immunity and sometimes resulting in overdose. chronic opioid treatment impairs macrophage progenitor cells and lymphocyte proliferation. Furthermore, opioids have a considerable effect on the differentiated activities of immune cells. Opioids accomplish this by acting directly on target cells or indirectly through centrally mediated pathways [<xref rid="ref56" ref-type="bibr">56</xref>].</p><p>Various medications including methadone, buprenorphine, naltrexone, buprenorphine with naltrexone combination, and levomethadyl acetate/levo-alpha-acetylmethadol are used and well studied for opioid use disorder as maintenance or detoxification therapy (<xref rid="T1" ref-type="table">Table 1</xref>). Buprenorphine, methadone, and naltrexone are the drugs used for medication-assisted treatment. According to the national practice guideline by the American Society of Addiction Medicine, psychosocial therapy should be offered to patients on oral therapy and extended-release naltrexone [<xref rid="ref57" ref-type="bibr">57</xref>]. the role of an extended-release formulation of naltrexone without psychosocial therapy has not been established. Out of the above three drugs, buprenorphine and methadone are categorized as essential drugs according toby the WHO [<xref rid="ref58" ref-type="bibr">58</xref>].</p><table-wrap position="float" id="T1" orientation="portrait"><label>TABLE 1</label><caption><p>Various medications used for opioid use disorder <bold>substance</bold></p></caption><table frame="border" rules="rows"><thead valign="top"><tr><th align="left" rowspan="1" colspan="1">Substance</th><th align="left" rowspan="1" colspan="1">Mechanism of action</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="1" colspan="1">Methadone, LAAM</td><td align="left" rowspan="1" colspan="1">Opioid agonist</td></tr><tr><td align="left" rowspan="1" colspan="1">Buprenorphine</td><td align="left" rowspan="1" colspan="1">Opioid partial agonist</td></tr><tr><td align="left" rowspan="1" colspan="1">Naltrexone</td><td align="left" rowspan="1" colspan="1">Opioid antagonist</td></tr><tr><td align="left" rowspan="1" colspan="1">Buprenorphine/&#8211; naltrexone</td><td align="left" rowspan="1" colspan="1">Opioid partial agonist/antagonist</td></tr><tr><td align="left" rowspan="1" colspan="1">Lofexidine</td><td align="left" rowspan="1" colspan="1">&#945;2 agonist</td></tr></tbody></table><table-wrap-foot><fn id="TF1-1"><p>LAAM &#8211; levomethadyl acetate</p></fn></table-wrap-foot></table-wrap><p>Methadone is an FDA-approved drug for opioid detoxication and maintenance therapy. it is a muopioid receptor agonist and has properties similar to morphine. l-methadone has 5&#8211;30 times higher potency than D-methadone, lacking addiction potential and respiratory depressant effects. Properties such as adequate oral bioavailability, longer duration of action, and an extended duration of withdrawal suppressing effects in the opioid-addicted patient make methadone maintenance therapy attractive to physicians. Other impacts on cough suppression, action on biliary tone, and other effects are similar to morphine. Plasma levels are detectable 30 minutes following oral ingestion and peak at 4 hours. the liver is the primary organ of metabolism, and pyrrolidine and pyrroline are the primary metabolites. the half-life of methadone is 15&#8211;40 hours. there is a risk of drug accumulation after repeated administration. the respiratory depressant effects lag behind the peak analgesia. tolerance and dependence are not uncommon with methadone, as with other opiates. the typical dose used for maintenance therapy is 2.5 to 10 mg every 8 to 12 hours. the adverse effects of methadone are similar to those of other opiates. in addition to the typical side effects, the adverse effect that needs partICUlar attention is Qt prolongation. close cardiac monitoring must be done, especially when the patient is on multiple drugs causing Qt prolongation [<xref rid="ref59" ref-type="bibr">59</xref>]. A retrospective study conducted by Patel <italic toggle="yes">et al</italic>. [<xref rid="ref60" ref-type="bibr">60</xref>] from 2012 to 2016 in the ICU found no significant increase in Qtc interval with low-dose methadone therapy. in critically ill patients, protocolised methadone therapy reduces the length of mechanical ventilation, weans from opiate infusion, and improves the prognosis [<xref rid="ref61" ref-type="bibr">61</xref>].</p><p>Buprenorphine, a mu receptor partial agonist, kappa antagonist, delta agonist, and ORl-1 receptor partial agonist, is commonly used for opioid use disorder as maintenance therapy. the peculiar pharmacological profile (only a ceiling effect on respiratory depression, not analgesic properties) attracts physicians to use buprenorphine in an office-based setting, unlike methadone, which is mainly prescribed in authorized deaddiction centres [<xref rid="ref62" ref-type="bibr">62</xref>]. Buprenorphine has less toxicity due to overdose. Different formulations of buprenorphine are used and studied for maintenance therapy and chronic pain [<xref rid="ref63" ref-type="bibr">63</xref>, <xref rid="ref64" ref-type="bibr">64</xref>]. Buprenorphine buccal film has been studied for chronic low back pain [<xref rid="ref65" ref-type="bibr">65</xref>]. the sublingual route is preferred for opioid maintenance therapy.</p><p>Buprenorphine rotation is a promising new strategy that can be used instead of tapering long-term opioid therapy (ltOt). A systematic review conducted by Powell <italic toggle="yes">et al</italic>. [<xref rid="ref66" ref-type="bibr">66</xref>], including 22 studies, showed that buprenorphine therapy reduced chronic pain intensity without precipitating opioid withdrawal symptoms. A novel strategy for starting buprenorphine and naloxone has been described in a critically ill intubated patient with an opioid use disorder using a rapid micro-induction (micro- dosing) technique. it entails the use of small, frequent doses of buprenorphine or naloxone that do not trigger withdrawal symptoms [<xref rid="ref67" ref-type="bibr">67</xref>]. According to the results of a prospective study, it was found that the use of buprenorphine and naloxone improved sleep and depression when used for medication-assisted therapy [<xref rid="ref68" ref-type="bibr">68</xref>]. According to the recommendation of Nice guidelines in the UK, buprenorphine and methadone are the first-line therapies for both opioid maintenance and medically assisted withdrawal therapy [<xref rid="ref69" ref-type="bibr">69</xref>]. in opioid substitution therapy, buprenorphine is six times safer than methadone in the event of a drug overdose [<xref rid="ref70" ref-type="bibr">70</xref>]. in the SUMMit trial involving 361 opiate-dependent individuals, patients on methadone therapy had higher incidence of substance abuse and physical and psychiatric issues than those on buprenorphine [<xref rid="ref71" ref-type="bibr">71</xref>]. Due to the abuse potential and severe adverse effects of a methadone drug overdose, such as respiratory depression and Qt prolongation, the naloxone-buprenorphine combination has gained importance. this drug combination has less abuse potential. Buprenorphine and naloxone are available in a 4 : 1 ratio.</p><p>The FDA approved levo-methyl acetate hydro-chloride (lAAM) for maintenance therapy in 1993 [<xref rid="ref72" ref-type="bibr">72</xref>]. According to a review, lAAM therapy is associated with less use of heroin, but adherence to therapy is better than methadone therapy [<xref rid="ref73" ref-type="bibr">73</xref>]. However, owing to the Qt prolongation and torsade de pointes effects due to the potassium channel blocking effects [<xref rid="ref74" ref-type="bibr">74</xref>], the european Medical Agency suspended the marketing of lAAM in 2001. the United States Food and Drug Administration placed a black box warning on the label for lAAM [<xref rid="ref75" ref-type="bibr">75</xref>]. induction with a higher dose of lAAM may be associated with a higher patient dropout rate as well as an adverse effect [<xref rid="ref76" ref-type="bibr">76</xref>].</p><p>Opioid antagonists such as naltrexone block the euphoric effect of opiates and prevent physical dependence due to opioid addiction. intramuscular extended-release naltrexone is approved by the Food and Drug Administration for treating opioid and alcohol use disorders [<xref rid="ref77" ref-type="bibr">77</xref>]. Due to the poor adherence risk with oral naltrexone therapy, sustained-release naltrexone preparations have been developed. Naltrexone therapy with either individual or group psychosocial therapy is associated with a better outcome [<xref rid="ref78" ref-type="bibr">78</xref>]. tramadol may be considered an alternative to methadone or buprenorphine for opioid withdrawal symptoms, but studies are limited [<xref rid="ref79" ref-type="bibr">79</xref>].</p></sec><sec id="S4"><title>NON-OPIOID THERAPY IN THE INTENSIVE CARE UNIT</title><p>Opioids are the primary pharmacological agent for analgo-sedation in the intensive care unit. Given concerns regarding the opioid epidemic, non- opioid analgesic agents should be used to combat the crisis. According to one recent systematic review and meta-analysis, the use of adjuvant anal-gesic agents in addition to an opioid was associated with a reduced pain score at 24 h as compared to opioid alone therapy [<xref rid="ref79" ref-type="bibr">79</xref>]. Opioid consumption was reduced using adjuvant analgesic agents (in oral morphine equivalents per 24 h, 25.89 mg less; 95% ci: 19.97&#8211;31.81 mg) [<xref rid="ref80" ref-type="bibr">80</xref>].</p><p>According to the PADiS algorithm, individuals at risk of opioid-related adverse effects should receive an adjuvant non-opioid-based analgesic [<xref rid="ref81" ref-type="bibr">81</xref>]. Nociceptive pain can be managed with acetaminophen, nefopam, or low-dose ketamine, whereas neuropathic pain can be managed with gabapentin, pregabalin, and carbamazepine.</p><p>In the ICU, non-opioid analgesics and adjuvant agents such as neuropathic agents are alternatives to opioid use in these patients.</p><p>According to one study, 64% of patients receive paracetamol in the ICU [<xref rid="ref82" ref-type="bibr">82</xref>]. it is a safe and effective option for ICU patients. Paracetamol is available in intravenous, oral, and rectal preparations [<xref rid="ref83" ref-type="bibr">83</xref>].</p><p>Non-steroidal anti-inflammatory drugs (NSAiDs) block the cOX-1 and cOX-2 receptors and decrease prostaglandin synthesis. Apart from postoperative patients admitted to the ICU, there are limited data regarding the analgesic efficacy of NSAiDs in critically ill patients [<xref rid="ref84" ref-type="bibr">84</xref>]. NSAiDs should be avoided in patients with allergies, renal dysfunction, gastrointestinal bleeding, and platelet dysfunction. Because of these predicted adverse effects, PADiS guidelines advise against the routine use of NSAiDs despite their opioid-sparing effects [<xref rid="ref81" ref-type="bibr">81</xref>].</p><p>Ketamine is an analgesic and sedative agent that acts as an NMDA receptor antagonist. low-dose ketamine infusion in ICU patients is associated with reduced opioid requirements and a minimal impact on haemodynamics [<xref rid="ref85" ref-type="bibr">85</xref>].</p><p>Other non-opioid drugs are worth considering, for example, a-2 agonists, whose central sympatholytic effects are potentially useful in managing opioid withdrawal symptoms. clonidine was popularised as a non-opioid agent for relieving withdrawal symptoms [<xref rid="ref86" ref-type="bibr">86</xref>], but hypotension is a significant side effect of clonidine that limits its use. lofexidine is one of the drugs in that group studied to treat opioidwithdrawal disorder [<xref rid="ref87" ref-type="bibr">87</xref>]. Medication-assisted the rapy (MAT) is a combination of medications with behavio ural or psychosocial counselling for opioid addicts [<xref rid="ref88" ref-type="bibr">88</xref>]. Psychosocial treatment has a better outcome profile than treatments with only medications [<xref rid="ref89" ref-type="bibr">89</xref>]. MAT has a role in decreasing opioid-related deaths, infectious disease transmission, and criminal activities resulting from opioid dependence [<xref rid="ref88" ref-type="bibr">88</xref>]. the goal of psychosocial therapy should include assessing psychosocial needs, supportive counselling, behaviour therapy to adhere to the prescribed medication, individual, group, or family counselling, and treatment of other psychiatric disorders [<xref rid="ref89" ref-type="bibr">89</xref>, <xref rid="ref90" ref-type="bibr">90</xref>]. counselling the patient and caregiver is crucial in rehabilitation programmes and prevents post-intensive care opioid dependence. One should be aware of the potential risks associated with opioid analgesics, including the risk of dependence, tolerance, and danger signs of overdose. Acupuncture, transcutaneous electrical nerve stimulation (teNS), massage, and music therapy may be beneficial adjuncts to drugs in these individuals&#8217; pain management. in opioid-dependent individuals, regional analgesia may be an effective adjunct to systemic analgesics [<xref rid="ref91" ref-type="bibr">91</xref>].</p></sec><sec id="S5"><title>OPIOID WITHDRAWAL</title><p>Due to the increased importance of analgosedation in the ICU to prevent the risk of delirium, opioids have become a vital agent for analgesia. According to one study, the overall incidence of iatrogenic opioid withdrawal was 16.7% and it was associated with continuous opioid infusion for more than three days [<xref rid="ref92" ref-type="bibr">92</xref>]. iatrogenic opioid withdrawal is mainly observed with remifentanil, fentanyl, and morphine [<xref rid="ref93" ref-type="bibr">93</xref>]. there are many strategies to treat this opioid withdrawal in ICU patients, e.g. substituting short-acting opioids with longer-acting opioids and gradually decreasing opioids in a stepwise manner [<xref rid="ref91" ref-type="bibr">91</xref>]. the intensivist&#8217;s role is to prevent episodes of iatrogenic opioid withdrawal by adapting non-opioid-based analgesic agents and using regional analgesia [<xref rid="ref94" ref-type="bibr">94</xref>].</p><p>These patients may develop opioid withdrawal symptoms, and methadone, buprenorphine, cloni-dine, and lofexidine are generally prescribed to combat this issue. the selective a-2 agonist dexmedetomidine has been administered to treat the hyperactive symptoms of opiate withdrawal [<xref rid="ref91" ref-type="bibr">91</xref>]. Adequate titration of opioids for appropriate anal-gesia in a patient with withdrawal is a challenge for intensivists, and there is no definite guideline regarding the issue. the clinical Opioid withdrawal Scale (cOwS) is a valuable tool for deciding the need and dose of a pharmacologic agent for opioid withdrawal [<xref rid="ref95" ref-type="bibr">95</xref>]. Sometimes, in patients with a history of addiction to crude opium preparations, it is difficult to determine the actual dose and composition of opioids. compliance with pharmacologic therapy is not always adequate, which leads to the discontinuation of therapy and switching to crude preparations [<xref rid="ref96" ref-type="bibr">96</xref>]. counselling of the caregiver regarding the need for maintenance and drug therapy is an essential component.</p></sec><sec id="S6"><title>CHRONIC ICU-RELATED PAIN</title><p>Another major issue that should not be overlooked is persistent pain in ICU survivors. Diffe rent researchers have a wide range of definitions of persistent or chronic ICU-related pain (CIRP) [<xref rid="ref97" ref-type="bibr">97</xref>]. the highest incidence rates of persistent pain are 77% and 36% after three months and two years after ICU discharge [<xref rid="ref98" ref-type="bibr">98</xref>]. the adverse consequences of CIRP lead to prolonged opioid use in intensive care survivors and the progression to opioid addiction. Duration and intensity of pain are the risk factors for developing CIRP. A multimodal analgesic approach with non-opioid analgesics should be used to prevent CIRP.</p><p>Postoperative pain has multiple complications, including cardiovascular effects due to activation of the sympathetic nervous system, risk of thromboembolism and progression to chronic pain, and increased hospital stay. Opioids have been the primary pharmacological medicine for perioperative analgesia. However, opioid use in the perioperative period could promote the long-term use of opioids. chronic opioid dependence is associated with risk factors such as pre-operative tobacco or alcohol abuse, younger age group, mood disorders, and pain disorders. the American college of Surgeons and the American Society of Anesthesiologists suggested non-opioid analgesic agents for perioperative pain control and calculated the use of opioids on discharge prescriptions [<xref rid="ref99" ref-type="bibr">99</xref>]. Multimodal analgesia with non-opioid analgesic agents, anti-depressants, and anticonvulsants are some promising options for preventing opioid-related adverse effects in the ICU.</p></sec><sec sec-type="conclusions" id="S7"><title>CONCLUSIONS</title><p>The opioid epidemic is a real threat to the nation&#8217;s health and from a socio-economical point of view. control and monitoring of over-prescription of opioids should be carried out to combat the opioid epidemic. Preference for non-opioid analgesics, management of acute pain in the ICU to prevent chronic pain syndromes, and education of patients and their care providers are vital to preventing this epidemic. the opioid-sparing strategy should be followed in the early postoperative period in the intensive care unit. Maintenance therapy with either methadone or buprenorphine and psychosocial counselling of the individual and their family members are vital to treat opioid addiction. An inten sivist should plan opioid detoxification or maintenance therapy after the clinical improvement of ICU patients.</p></sec></body><back><ack><title>ACKNOWLEDGMENTS</title></ack><sec sec-type="financial-disclosure" id="S8"><title>Financial support and sponsorship</title><p>none.</p></sec><sec sec-type="COI-statement" id="S9"><title>Conflicts of interest</title><p>none.</p></sec><ref-list><ref id="ref1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Principles of analgesic use in the treatment of acute pain and chronic cancer pain, 2nd edition</collab></person-group>. <part-title>American Pain Society</part-title>. <source>Clin Pharm</source><year>1990</year>; <volume>9</volume>: <fpage>601</fpage>-<lpage>612</lpage>.<pub-id pub-id-type="pmid">2201478</pub-id></mixed-citation></ref><ref id="ref2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Centers for Disease Control and Prevention (CDC)</collab></person-group>. <article-title>Vital signs: overdoses of prescription opioid pain relievers&#8211;United States, 1999-2008</article-title>. <source>MMWR Morb Mortal Wkly Rep</source><year>2011</year>; <volume>60</volume>: <fpage>1487</fpage>-<lpage>1492</lpage>.<pub-id pub-id-type="pmid">22048730</pub-id></mixed-citation></ref><ref id="ref3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Centers for Disease Control and Prevention (CDC)</collab></person-group>. <article-title>Vital signs: overdoses of prescription opioid pain relievers and other drugs among women&#8211;United States, 1999-2010</article-title>. <source>MMWR Morb Mortal Wkly Rep</source><year>2013</year>; <volume>62</volume>: <fpage>537</fpage>-<lpage>542</lpage>.<pub-id pub-id-type="pmid">23820967</pub-id><pub-id pub-id-type="pmcid">PMC4604783</pub-id></mixed-citation></ref><ref id="ref4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gladden</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Martinez</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Seth</surname><given-names>P</given-names></string-name></person-group>. <article-title>Fentanyl law enforcement submissions and increases in synthetic opioid-involved overdose deaths&#8211;27 states, 2013-2014</article-title>. <source>MMWR Morb Mortal Wkly Rep</source><year>2016</year>; <volume>65</volume>: <fpage>837</fpage>-<lpage>843</lpage>. doi: <pub-id pub-id-type="doi">10.15585/mmwr.mm6533a2</pub-id>.<pub-id pub-id-type="pmid">27560775</pub-id></mixed-citation></ref><ref id="ref5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>O&#8217;Donnell</surname><given-names>JK</given-names></string-name>, <string-name name-style="western"><surname>Gladden</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Seth</surname><given-names>P</given-names>.</string-name></person-group><article-title>Trends in deaths involving heroin and synthetic opioids excluding methadone, and law enforcement drug product reports, by census region&#8211;United States, 2006-2015</article-title>. <source>MMWR Morb Mortal Wkly Rep</source><year>2017</year>; <volume>66</volume>: <fpage>897</fpage>-<lpage>903</lpage>. doi: <pub-id pub-id-type="doi">10.15585/mmwr.mm6634a2</pub-id>.<pub-id pub-id-type="pmid">28859052</pub-id><pub-id pub-id-type="pmcid">PMC5657786</pub-id></mixed-citation></ref><ref id="ref6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>O&#8217;Donnell</surname><given-names>JK</given-names></string-name>, <string-name name-style="western"><surname>Halpin</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Mattson</surname><given-names>CL</given-names></string-name>, <string-name name-style="western"><surname>Goldberger</surname><given-names>BA</given-names></string-name>, <string-name name-style="western"><surname>Gladden</surname><given-names>RM</given-names></string-name></person-group>. <article-title>Deaths involving fentanyl, fentanyl analogs, and U-47700&#8211;10 states, July-December 2016</article-title>. <source>MMWR Morb Mortal Wkly Rep</source><year>2017</year>; <volume>66</volume>: <fpage>1197</fpage>-<lpage>1202</lpage>. doi: <pub-id pub-id-type="doi">10.15585/mmwr.mm6643e1</pub-id>.<pub-id pub-id-type="pmid">29095804</pub-id><pub-id pub-id-type="pmcid">PMC5689219</pub-id></mixed-citation></ref><ref id="ref7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Seth</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Rudd</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Noonan</surname><given-names>RK</given-names></string-name>, <string-name name-style="western"><surname>Haegerich</surname><given-names>TM</given-names></string-name></person-group>. <article-title>Quantifying the epidemic of prescription opioid overdose deaths</article-title>. <source>Am J Public Health</source><year>2018</year>; <volume>108</volume>: <fpage>500</fpage>-<lpage>502</lpage>. doi: <pub-id pub-id-type="doi">10.2105/AJPH.2017.304265</pub-id>.<pub-id pub-id-type="pmid">29513577</pub-id><pub-id pub-id-type="pmcid">PMC5844400</pub-id></mixed-citation></ref><ref id="ref8"><label>8</label><mixed-citation publication-type="webpage"><article-title>Drug Enforcement Administration, US Department of Justice</article-title>; <year>2018</year>. <comment>Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.justice.gov/file/968916/download" ext-link-type="uri">https://www.justice.gov/file/968916/download</ext-link></comment>.</mixed-citation></ref><ref id="ref9"><label>9</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>New Mexico Office of the Medical Examiner</collab></person-group>. <article-title>Forensic toxicology</article-title>; <year>2018</year>. <comment>Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://omi.unm.edu" ext-link-type="uri">https://omi.unm.edu</ext-link></comment>.</mixed-citation></ref><ref id="ref10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Drug Enforcement Administration, US Department of Justice</collab></person-group>. <article-title>Schedules of controlled substances: temporary placement of acetyl fentanyl into schedule I, final order</article-title>. <source>Fed Regist</source><year>2015</year>; <volume>80</volume>: <fpage>42381</fpage>-<lpage>42385</lpage>.<pub-id pub-id-type="pmid">26189217</pub-id></mixed-citation></ref><ref id="ref11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Drug Enforcement Administration, US Department of Justice</collab></person-group>. <article-title>Schedules of controlled substances: temporary placement of furanyl fentanyl into schedule I, final order</article-title>. <source>Fed Regist</source><year>2016</year>; <volume>81</volume>: <fpage>85873</fpage>-<lpage>85877</lpage>.<pub-id pub-id-type="pmid">27906535</pub-id></mixed-citation></ref><ref id="ref12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Drug Enforcement Administration, US Department of Justice</collab></person-group>. <article-title>Sche dules of controlled substances: temporary placement of 4-fluoroisobutyryl fentanyl into schedule I, temporary scheduling order</article-title>. <source>Fed Regist</source><year>2017</year>; <volume>82</volume>: <fpage>20544</fpage>-<lpage>20548</lpage>.<pub-id pub-id-type="pmid">28497944</pub-id></mixed-citation></ref><ref id="ref13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Drug Enforcement Administration, US Department of Justice</collab></person-group>. <article-title>Sche dules of controlled substances: temporary placement of cyclopropyl fentanyl in schedule I, temporary amendment; temporary scheduling order</article-title>. <source>Fed Regist</source><year>2018</year>; <volume>83</volume>: <fpage>469</fpage>-<lpage>472</lpage>.<pub-id pub-id-type="pmid">29319947</pub-id></mixed-citation></ref><ref id="ref14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Drug Enforcement Administration, US Department of Justice</collab></person-group>. <article-title>Schedules of controlled substances: temporary placement of U-47700 into schedule I, final order</article-title>. <source>Fed Regist</source><year>2016</year>; <volume>81</volume>: <fpage>79389</fpage>-<lpage>79393</lpage>.<pub-id pub-id-type="pmid">27905978</pub-id></mixed-citation></ref><ref id="ref15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bicket</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Long</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Pronovost</surname><given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Alexander</surname><given-names>GC</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>CL</given-names></string-name></person-group>. <article-title>Prescription opioid analgesics commonly unused after surgery: a systematic review</article-title>. <source>JAMA Surg</source><year>2017</year>; <volume>152</volume>: <fpage>1066</fpage>-<lpage>1071</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jamasurg.2017.0831</pub-id>.<pub-id pub-id-type="pmid">28768328</pub-id><pub-id pub-id-type="pmcid">PMC5701659</pub-id></mixed-citation></ref><ref id="ref16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Theisen</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Jacobs</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Macleod</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Davies</surname><given-names>B</given-names></string-name></person-group>. <article-title>The United States opioid epidemic: a review of the surgeon&#8217;s contribution to it and health policy initiatives</article-title>. <source>BJU Int</source><year>2018</year>; <volume>122</volume>: <fpage>754</fpage>-<lpage>759</lpage>. doi: <pub-id pub-id-type="doi">10.1111/bju.14446</pub-id>.<pub-id pub-id-type="pmid">29896932</pub-id></mixed-citation></ref><ref id="ref17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Stevens</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Wall</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Novack</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Marshall</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hsu</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Howell</surname><given-names>M</given-names></string-name></person-group>. <article-title>The critical care crisis of opioid overdoses in the United States</article-title>. <source>Ann Am Thorac Soc</source><year>2017</year>; <volume>14</volume>: <fpage>1803</fpage>-<lpage>1809</lpage>. doi: <pub-id pub-id-type="doi">10.1513/AnnalsATS.201701-022OC</pub-id>.<pub-id pub-id-type="pmid">28800256</pub-id><pub-id pub-id-type="pmcid">PMC5802515</pub-id></mixed-citation></ref><ref id="ref18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Burry</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Willliamson</surname><given-names>DR</given-names></string-name>, <string-name name-style="western"><surname>Perreault</surname><given-names>MM</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Analgesic, sedative, anti-psychotic, and neuromuscular blocker use in Canadian intensive care units: a prospective, multicentre, observational study</article-title>. <source>Can J Anaesth</source><year>2014</year>; <volume>61</volume>: <fpage>619</fpage>-<lpage>630</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12630-014-0174-1</pub-id>.<pub-id pub-id-type="pmid">24788564</pub-id></mixed-citation></ref><ref id="ref19"><label>19</label><mixed-citation publication-type="webpage"><article-title>Emergency preparedness and response: Increase in fatal drug overdoses across the United States driven by synthetic opioids before and during the COVID-19 pandemic</article-title><year>2020</year>. <comment>Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://emergency.cdc.gov/han/2020/han00438.asp" ext-link-type="uri">https://emergency.cdc.gov/han/2020/han00438.asp</ext-link></comment>.</mixed-citation></ref><ref id="ref20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Slavova</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Rock</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Bush</surname><given-names>HM</given-names></string-name>, <string-name name-style="western"><surname>Quesinberry</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Walsh</surname><given-names>SL</given-names></string-name></person-group>. <article-title>Signal of increased opioid overdose during COVID-19 from emergency medical services data</article-title>. <source>Drug Alcohol Depend</source><year>2020</year>; <volume>214</volume>: <fpage>108176</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2020.108176</pub-id>.<pub-id pub-id-type="pmid">32717504</pub-id><pub-id pub-id-type="pmcid">PMC7351024</pub-id></mixed-citation></ref><ref id="ref21"><label>21</label><mixed-citation publication-type="webpage"><article-title>Increase in fatal drug overdoses across the United States driven by synthetic opioids before and during the COVID-19 pandemic</article-title>. <year>2020</year>. <comment>Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://emergency.cdc.gov/han/2020/han00438.asp" ext-link-type="uri">https://emergency.cdc.gov/han/2020/han00438.asp</ext-link> (Accessed: 13.01.2022)</comment>.</mixed-citation></ref><ref id="ref22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Niles</surname><given-names>JK</given-names></string-name>, <string-name name-style="western"><surname>Gudin</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Radcliff</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kaufman</surname><given-names>HW</given-names></string-name></person-group>. <article-title>The opioid epidemic within the COVID-19 pandemic: drug testing in 2020</article-title>. <source>Popul Health Manag</source><year>2021</year>; <volume>24</volume>: <fpage>S43</fpage>-<lpage>S51</lpage>. doi: <pub-id pub-id-type="doi">10.1089/pop.2020.0230</pub-id>.<pub-id pub-id-type="pmid">33031013</pub-id><pub-id pub-id-type="pmcid">PMC7875135</pub-id></mixed-citation></ref><ref id="ref23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tischler</surname><given-names>V</given-names></string-name></person-group>. <article-title>Dr Junkie. The Doctor addict in Bulgakov&#8217;s morphine: what are the lessons for contemporary medical practice</article-title>. <source>J Med Humanit</source><year>2015</year>; <volume>36</volume>: <fpage>359</fpage>-<lpage>368</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10912-013-9259-z</pub-id>.<pub-id pub-id-type="pmid">24221860</pub-id><pub-id pub-id-type="pmcid">PMC4642586</pub-id></mixed-citation></ref><ref id="ref24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Walter</surname><given-names>H</given-names></string-name></person-group>. <article-title>&#8220;Epidemic&#8221; or peripheral phenomenon?: a medical history of the &#8220;cocaine wave&#8221; in the Weimar Republic</article-title>. <source>NTM</source><year>2017</year>; <volume>25</volume>: <fpage>311</fpage>-<lpage>348</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00048-017-0174-7</pub-id> [Article in German].<pub-id pub-id-type="pmid">28721525</pub-id></mixed-citation></ref><ref id="ref25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>El-Tallawy</surname><given-names>SN</given-names></string-name>, <string-name name-style="western"><surname>Nalamasu</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Pergolizzi</surname><given-names>JV</given-names></string-name>, <string-name name-style="western"><surname>Gharibo</surname><given-names>C</given-names></string-name></person-group>. <article-title>Pain management during the COVID-19 pandemic</article-title>. <source>Pain Ther</source><year>2020</year>; <volume>25</volume>: <fpage>1</fpage>-<lpage>4</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s40122-020-00190-4</pub-id>.<pub-id pub-id-type="pmcid">PMC7445106</pub-id><pub-id pub-id-type="pmid">32840756</pub-id></mixed-citation></ref><ref id="ref26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Haley</surname><given-names>DF</given-names></string-name>, <string-name name-style="western"><surname>Saitz</surname><given-names>R</given-names></string-name></person-group>. <article-title>The opioid epidemic during the COVID-19 pandemic</article-title>. <source>JAMA</source><year>2020</year>; <volume>324</volume>: <fpage>1615</fpage>-<lpage>1617</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jama.2020.18543</pub-id>.<pub-id pub-id-type="pmid">32945831</pub-id></mixed-citation></ref><ref id="ref27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Alexander</surname><given-names>GC</given-names></string-name>, <string-name name-style="western"><surname>Stoller</surname><given-names>KB</given-names></string-name>, <string-name name-style="western"><surname>Haffajee</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Saloner</surname><given-names>B</given-names></string-name></person-group>. <article-title>an epidemic in the midst of a pandemic: opioid use disorder and COVID-19</article-title>. <source>Ann Intern Med</source><year>2020</year>; <volume>173</volume>: <fpage>57</fpage>-<lpage>58</lpage>. doi: <pub-id pub-id-type="doi">10.7326/M20-1141</pub-id>.<pub-id pub-id-type="pmid">32240283</pub-id><pub-id pub-id-type="pmcid">PMC7138407</pub-id></mixed-citation></ref><ref id="ref28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Qeadan</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Tingey</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Bern</surname><given-names>R</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Opioid use disorder and health service utilization among COVID-19 patients in the US: a nationwide cohort from the Cerner Real-World Data</article-title>. <source>Clin Med</source><year>2021</year>; <volume>37</volume>: <fpage>100938</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.eclinm.2021.100938</pub-id>.<pub-id pub-id-type="pmcid">PMC8177438</pub-id><pub-id pub-id-type="pmid">34109308</pub-id></mixed-citation></ref><ref id="ref29"><label>29</label><mixed-citation publication-type="webpage"><article-title>Centers for Disease Control and Prevention</article-title>. <comment>Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/media/releases/2020/p1218-overdose-deaths-COVID-19.html" ext-link-type="uri">https://www.cdc.gov/media/releases/2020/p1218-overdose-deaths-COVID-19.html</ext-link></comment>.</mixed-citation></ref><ref id="ref30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rajagopal</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Karim</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Booth</surname><given-names>CM</given-names></string-name></person-group>. <article-title>Oral morphine use in south India: a population-based study</article-title>. <source>J Glob Oncol</source><year>2017</year>; <volume>3</volume>: <fpage>720</fpage>-<lpage>727</lpage>. doi: <pub-id pub-id-type="doi">10.1200/JGO.2016.007872</pub-id>.<pub-id pub-id-type="pmid">29244992</pub-id><pub-id pub-id-type="pmcid">PMC5735973</pub-id></mixed-citation></ref><ref id="ref31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rajagopal</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Joranson</surname><given-names>DE</given-names></string-name></person-group>. <article-title>India: opioid availability. An update</article-title>. <source>J Pain Symptom Manage</source><year>2007</year>; <volume>33</volume>: <fpage>615</fpage>-<lpage>622</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jpainsymman</pub-id>.<pub-id pub-id-type="pmid">17482057</pub-id></mixed-citation></ref><ref id="ref32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rajagopal</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Joranson</surname><given-names>DE</given-names></string-name>, <string-name name-style="western"><surname>Gilson</surname><given-names>AM</given-names></string-name></person-group>. <article-title>Medical use, misuse, and diversion of opioids in India</article-title>. <source>Lancet</source><year>2001</year>; <volume>14</volume>: <fpage>139</fpage>-<lpage>143</lpage>. doi: <pub-id pub-id-type="doi">10.1016/s0140-6736(01)05322-3</pub-id>.<pub-id pub-id-type="pmid">11463435</pub-id></mixed-citation></ref><ref id="ref33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rajagopal</surname><given-names>MR</given-names></string-name></person-group>. <article-title>The current status of palliative care in India</article-title>. <source>Cancer Control</source><year>2015</year>; <volume>22</volume>: <fpage>57</fpage>-<lpage>62</lpage>.</mixed-citation></ref><ref id="ref34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sharma</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Arora</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Kaur</surname><given-names>P</given-names></string-name></person-group>. <article-title>Drug abuse: uncovering the burden in rural Punjab</article-title>. <source>J Fam Med Primary Care</source><year>2017</year>; <volume>6</volume>: <fpage>558</fpage>. doi: <pub-id pub-id-type="doi">10.4103/2249-4863.222037</pub-id>.<pub-id pub-id-type="pmcid">PMC5787955</pub-id><pub-id pub-id-type="pmid">29417008</pub-id></mixed-citation></ref><ref id="ref35"><label>35</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Ray</surname><given-names>R</given-names></string-name></person-group> (ed.). <part-title>The extent, pattern &amp; trends of drug abuse in India: National survey</part-title>. <publisher-loc>New Delhi</publisher-loc>: <publisher-name>Ministry of Social Justice and Empowerment, Government of India &amp; United Nations Office on Drugs and Crime, Regional Office For South Asia</publisher-name>; <year>2004</year>.</mixed-citation></ref><ref id="ref36"><label>36</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>Ministry of Social Justice and Empowerment</collab></person-group>. <part-title>Magnitude of substance use in India</part-title>. <publisher-loc>New Delhi</publisher-loc>: <publisher-name>MSJE, Government of India</publisher-name>; <year>2019</year>.</mixed-citation></ref><ref id="ref37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lakshminarayana</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname><given-names>MB</given-names></string-name></person-group>. <article-title>Opium addiction among rural population in desert districts of Western Rajasthan: some observations from the study</article-title>. <source>J Human Ecol</source><year>2009</year>; <volume>25</volume>: <fpage>1</fpage>-<lpage>4</lpage>. doi: <pub-id pub-id-type="doi">10.1080/09709274.2009.11906125</pub-id>.</mixed-citation></ref><ref id="ref38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Malviya</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Negi</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Mandora</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Yadav</surname><given-names>JK</given-names></string-name></person-group>. <article-title>Perioperative status and complications in opium addicts in Western Rajasthan</article-title>. <source>Indian J Surg</source><year>2011</year>; <volume>73</volume>: <fpage>346</fpage>-<lpage>351</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12262-011-0324-4</pub-id>.<pub-id pub-id-type="pmid">23024539</pub-id><pub-id pub-id-type="pmcid">PMC3208708</pub-id></mixed-citation></ref><ref id="ref39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rajagopal</surname><given-names>MR</given-names></string-name></person-group>. <article-title>Access to palliative care: insights into ground realities post-2014 amendment to NDPS Act</article-title>. <source>Indian J Med Ethics</source><year>2016</year>; <volume>1</volume>: <fpage>25</fpage>-<lpage>30</lpage>. doi: <pub-id pub-id-type="doi">10.20529/IJME.2016.006</pub-id>.<pub-id pub-id-type="pmid">26826658</pub-id></mixed-citation></ref><ref id="ref40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Math</surname><given-names>SB</given-names></string-name>, <string-name name-style="western"><surname>Mohan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>NC</given-names></string-name></person-group>. <article-title>Opioid substitution therapy: legal challenges</article-title>. <source>Indian J Psychiatry</source><year>2018</year>; <volume>60</volume>: <fpage>271</fpage>-<lpage>277</lpage>. doi: <pub-id pub-id-type="doi">10.4103/psychiatry.IndianJPsychiatry_391_18</pub-id>.<pub-id pub-id-type="pmid">30405251</pub-id><pub-id pub-id-type="pmcid">PMC6201678</pub-id></mixed-citation></ref><ref id="ref41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Parmar</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Patil</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Sarkar</surname><given-names>S</given-names></string-name></person-group>. <article-title>Natural opioid use in elderly in India: a case series</article-title>. <source>J Subst Use</source><year>2017</year>; <volume>4</volume>: <fpage>156</fpage>-<lpage>158</lpage>. doi: <pub-id pub-id-type="doi">10.3109/14659891.2016.1162211</pub-id>.</mixed-citation></ref><ref id="ref42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Parmar</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gupta</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Panda</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Bhad</surname><given-names>R</given-names></string-name></person-group>. <article-title>An observational study assessing the pathways to care among treatment-seeking users of natural opiates</article-title>. <source>Drugs</source><year>2020</year>; <volume>27</volume>: <fpage>199</fpage>-<lpage>204</lpage>. doi: <pub-id pub-id-type="doi">10.1080/09687637.2019.1649363</pub-id>.</mixed-citation></ref><ref id="ref43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sarkar</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ghosh</surname><given-names>A</given-names></string-name></person-group>. <article-title>The magnitude and vicissitudes of substance use disorders in India</article-title>. <source>Indian J Soc Psychiatry</source><year>2019</year>; <volume>35</volume>: <fpage>99</fpage>-<lpage>101</lpage>.</mixed-citation></ref><ref id="ref44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ambekar</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Rao</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Agrawal</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mishra</surname><given-names>AK</given-names></string-name></person-group>. <article-title>Punjab Opioid Dependence Survey</article-title>. <year>2015</year>. <comment>Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.pbhealth.gov.in/scan0003%20(2).pdf" ext-link-type="uri">http://www.pbhealth.gov.in/scan0003%20(2).pdf</ext-link></comment>.</mixed-citation></ref><ref id="ref45"><label>45</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Ray</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Kattimani</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sharma</surname><given-names>HK</given-names></string-name></person-group>. <article-title>Opium abuse and its management: Global scenario</article-title>. <person-group person-group-type="editor"><string-name name-style="western"><surname>Ray</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Kattimani</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sharma</surname><given-names>HK</given-names></string-name></person-group>. <source>Opium abuse and its management: Global scenario</source>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name>; <year>2006</year>. p. <fpage>1</fpage>-<lpage>13</lpage>. <comment>Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/substance_abuse/activities/opium_abuse_management.pdf" ext-link-type="uri">https://www.who.int/substance_abuse/activities/opium_abuse_management.pdf</ext-link></comment>.</mixed-citation></ref><ref id="ref46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ganguly</surname><given-names>KK</given-names></string-name>, <string-name name-style="western"><surname>Sharma</surname><given-names>HK</given-names></string-name>, <string-name name-style="western"><surname>Krishnamachari</surname><given-names>KA</given-names></string-name></person-group>. <article-title>An ethnographic account of opium consumers of Rajasthan (India): socio-medical perspective</article-title>. <source>Addiction</source><year>1995</year>; <volume>90</volume>: <fpage>9</fpage>-<lpage>12</lpage>; <comment>discussion 13-21</comment>.<pub-id pub-id-type="pmid">7534158</pub-id></mixed-citation></ref><ref id="ref47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Boscarino</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Hoffman</surname><given-names>SN</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>JJ</given-names></string-name></person-group>. <article-title>Opioid-use disorder among patients on long-term opioid therapy: impact of final DSM-5 diagnostic criteria on prevalence and correlates</article-title>. <source>Subst Abuse Rehabil</source><year>2015</year>; <volume>6</volume>: <fpage>83</fpage>. doi: <pub-id pub-id-type="doi">10.2147/SAR.S85667</pub-id>.<pub-id pub-id-type="pmid">26316838</pub-id><pub-id pub-id-type="pmcid">PMC4548725</pub-id></mixed-citation></ref><ref id="ref48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jones</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>McCance-Katz</surname><given-names>EF</given-names></string-name></person-group>. <article-title>Co-occurring substance use and mental disorders among adults with opioid use disorder</article-title>. <source>Drug Alcohol Depend</source><year>2019</year>; <volume>197</volume>: <fpage>78</fpage>-<lpage>82</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2018.12.030</pub-id>.<pub-id pub-id-type="pmid">30784952</pub-id></mixed-citation></ref><ref id="ref49"><label>49</label><mixed-citation publication-type="webpage"><article-title>Opioid overdose</article-title>. <year>2021</year>. <comment>Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/news-room/fact-sheets/detail/opioid-overdose" ext-link-type="uri">https://www.who.int/news-room/fact-sheets/detail/opioid-overdose</ext-link></comment>.</mixed-citation></ref><ref id="ref50"><label>50</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Understanding the Epidemic</collab></person-group>. <article-title>CDC&#8217;s Response to the Opioid Overdose Epidemic</article-title>; <year>2021</year>. <comment>Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/opioids/basics/epidemic.html" ext-link-type="uri">https://www.cdc.gov/opioids/basics/epidemic.html</ext-link></comment>.</mixed-citation></ref><ref id="ref51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Patel</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Walter</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>L</given-names></string-name></person-group>. <article-title>Opioid overdose crises during the COVID-19 pandemic: implication of health disparities</article-title>. <source>Harm Reduct J</source><year>2021</year>; <volume>18</volume>: <fpage>89</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12954-021-00534-z</pub-id>.<pub-id pub-id-type="pmid">34399771</pub-id><pub-id pub-id-type="pmcid">PMC8365290</pub-id></mixed-citation></ref><ref id="ref52"><label>52</label><mixed-citation publication-type="webpage"><article-title>5-Point Strategy To Combat the Opioid Crisis</article-title>. <year>2021</year>. <comment>Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.hhs.gov/opioids/about-the-epidemic/hhs-response/index.html" ext-link-type="uri">https://www.hhs.gov/opioids/about-the-epidemic/hhs-response/index.html</ext-link></comment>.</mixed-citation></ref><ref id="ref53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kalfon</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Boucekine</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Estagnasie</surname><given-names>P</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Risk factors and events in the adult intensive care unit associated with pain as self-reported at the end of the intensive care unit stay</article-title>. <source>Critical Care</source><year>2020</year>; <volume>24</volume>: <fpage>1</fpage>-<lpage>10</lpage>. doi: <pub-id pub-id-type="doi">10.1186/s13054-020-03396-2</pub-id>.<pub-id pub-id-type="pmid">33287910</pub-id><pub-id pub-id-type="pmcid">PMC7722444</pub-id></mixed-citation></ref><ref id="ref54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lewis</surname><given-names>KS</given-names></string-name>, <string-name name-style="western"><surname>Whipple</surname><given-names>JK</given-names></string-name>, <string-name name-style="western"><surname>Michael</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Quebbeman</surname><given-names>EJ</given-names></string-name></person-group>. <article-title>Effect of analgesic treatment on the physiological consequences of acute pain</article-title>. <source>Am J Hosp Pharm</source><year>1994</year>; <volume>51</volume>: <fpage>1539</fpage>-<lpage>1554</lpage>.<pub-id pub-id-type="pmid">8092155</pub-id></mixed-citation></ref><ref id="ref55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Skrobik</surname><given-names>Y</given-names></string-name></person-group>. <article-title>Insights into critical care and post-ICU opiate administration</article-title>. <source>Am J Respir Crit Care Med</source><year>2020</year>; <volume>15</volume>: <fpage>484</fpage>-<lpage>486</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1164/rccm.202005-1815ED</pub-id><pub-id pub-id-type="pmcid">PMC7427376</pub-id><pub-id pub-id-type="pmid">32464072</pub-id></mixed-citation></ref><ref id="ref56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Roy</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Loh</surname><given-names>HH</given-names></string-name></person-group>. <article-title>Effects of opioids on the immune system</article-title>. <source>Neurochem Res</source><year>1996</year>; <volume>21</volume>: <fpage>1375</fpage>-<lpage>1386</lpage>. doi: <pub-id pub-id-type="doi">10.1007/BF02532379</pub-id>.<pub-id pub-id-type="pmid">8947928</pub-id></mixed-citation></ref><ref id="ref57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kampman</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Jarvis</surname><given-names>M</given-names></string-name></person-group>. <article-title>American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use</article-title>. <source>J Addict Med</source><year>2015</year>; <volume>9</volume>: <fpage>358</fpage>-<lpage>367</lpage>. doi: <pub-id pub-id-type="doi">10.1097/ADM.0000000000000166</pub-id>.<pub-id pub-id-type="pmid">26406300</pub-id><pub-id pub-id-type="pmcid">PMC4605275</pub-id></mixed-citation></ref><ref id="ref58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Herget</surname><given-names>G</given-names></string-name></person-group>. <article-title>Methadone and Buprenorphine added to the WHO list of essential medicines</article-title>. <source>HIV AIDS Policy Law Rev</source><year>2005</year>; <volume>10</volume>: <fpage>23</fpage>-<lpage>24</lpage>.<pub-id pub-id-type="pmid">16544403</pub-id></mixed-citation></ref><ref id="ref59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Krantz</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Martin</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Stimmel</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Mehta</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Haigney</surname><given-names>MC</given-names></string-name></person-group>. <article-title>QTc interval screening in methadone treatment</article-title>. <source>Ann Intern Med</source><year>2009</year>; <volume>150</volume>: <fpage>387</fpage>-<lpage>395</lpage>. doi: <pub-id pub-id-type="doi">10.7326/0003-4819-150-6-200903170-00103</pub-id>.<pub-id pub-id-type="pmid">19153406</pub-id></mixed-citation></ref><ref id="ref60"><label>60</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Patel</surname><given-names>PH</given-names></string-name>, <string-name name-style="western"><surname>Cull</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sbertoli</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Patolia</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Jamkhana</surname><given-names>Z</given-names></string-name></person-group>. <part-title>Methadone use in the ICU: not as scary as you think. InC51. Critical care: more non-pulmonary critical care problems</part-title>. <source>American Thoracic Society</source><year>2017</year>; <fpage>A5777</fpage>.</mixed-citation></ref><ref id="ref61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Elefritz</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Murphy</surname><given-names>CV</given-names></string-name>, <string-name name-style="western"><surname>Papadimos</surname><given-names>TJ</given-names></string-name>, <string-name name-style="western"><surname>Lyaker</surname><given-names>MR</given-names></string-name></person-group>. <article-title>Methadone anal-gesia in the critically ill</article-title>. <source>J Crit Care</source><year>2016</year>; <volume>34</volume>: <fpage>84</fpage>-<lpage>88</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jcrc.2016.03.023</pub-id>.<pub-id pub-id-type="pmid">27288616</pub-id></mixed-citation></ref><ref id="ref62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Noe</surname><given-names>SR</given-names></string-name>, <string-name name-style="western"><surname>Keller</surname><given-names>T</given-names></string-name></person-group>. <article-title>Office-based buprenorphine treatment: identifying factors that promote retention in opioid-dependent patients</article-title>. <source>J Addict Nurs</source><year>2020</year>; <volume>31</volume>: <fpage>23</fpage>-<lpage>29</lpage>. doi: <pub-id pub-id-type="doi">10.1097/JAN.0000000000000320</pub-id>.<pub-id pub-id-type="pmid">32132421</pub-id></mixed-citation></ref><ref id="ref63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Steiner</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Sitar</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wen</surname><given-names>W</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naive patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study</article-title>. <source>J Pain Symptom Manage</source><year>2011</year>; <volume>42</volume>: <fpage>903</fpage>-<lpage>917</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jpainsymman.2011.04.006</pub-id>.<pub-id pub-id-type="pmid">21945130</pub-id></mixed-citation></ref><ref id="ref64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Corli</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Floriani</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Roberto</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized Phase IV &#8216;real life&#8217; trial on the variability of response to opioids</article-title>. <source>Ann Oncol</source><year>2016</year>; <volume>27</volume>: <fpage>1107</fpage>-<lpage>1115</lpage>. doi: <pub-id pub-id-type="doi">10.1093/annonc/mdw097</pub-id>.<pub-id pub-id-type="pmid">26940689</pub-id></mixed-citation></ref><ref id="ref65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gimbel</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Spierings</surname><given-names>EL</given-names></string-name>, <string-name name-style="western"><surname>Katz</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Xiang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Tzanis</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Finn</surname><given-names>A</given-names></string-name></person-group>. <article-title>Efficacy and tolerability of buccal buprenorphine in opioid-experienced patients with moderate to severe chronic low back pain: results of a Phase 3, enriched enrollment, randomized withdrawal study</article-title>. <source>Pain</source><year>2016</year>; <volume>157</volume>: <fpage>2517</fpage>-<lpage>2526</lpage>. doi: <pub-id pub-id-type="doi">10.1097/j.pain.0000000000000670</pub-id>.<pub-id pub-id-type="pmid">27434505</pub-id><pub-id pub-id-type="pmcid">PMC5065057</pub-id></mixed-citation></ref><ref id="ref66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Powell</surname><given-names>VD</given-names></string-name>, <string-name name-style="western"><surname>Rosenberg</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Yaganti</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Evaluation of buprenorphine rotation in patients receiving long-term opioids for chronic pain: a systematic review</article-title>. <source>JAMA Netw Open</source><year>2021</year>; <volume>4</volume>: <fpage>2124152</fpage>. doi: <pub-id pub-id-type="doi">10.1001/jamanetworkopen.2021.24152</pub-id>.<pub-id pub-id-type="pmcid">PMC8427372</pub-id><pub-id pub-id-type="pmid">34495339</pub-id></mixed-citation></ref><ref id="ref67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hamata</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Griesdale</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Hann</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Rezazadeh-Azar</surname><given-names>P</given-names></string-name></person-group>. <article-title>Rapid micro-induction of buprenorphine/naloxone for opioid use disorder in a critically ill intubated patient: a case report</article-title>. <source>J Addict Med</source><year>2020</year>; <volume>14</volume>: <fpage>514</fpage>-<lpage>517</lpage>. doi: <pub-id pub-id-type="doi">10.1097/ADM.0000000000000675</pub-id>.<pub-id pub-id-type="pmid">32649330</pub-id></mixed-citation></ref><ref id="ref68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zheng</surname><given-names>WH</given-names></string-name>, <string-name name-style="western"><surname>Wakim</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Geary</surname><given-names>RC</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Self-reported sleep improvement in buprenorphine MAT (medication-assisted treatment) population</article-title>. <source>Austin J Drug Abuse Addict</source><year>2016</year>; <volume>3</volume>: <fpage>1009</fpage>.<pub-id pub-id-type="pmid">28133635</pub-id><pub-id pub-id-type="pmcid">PMC5270620</pub-id></mixed-citation></ref><ref id="ref69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Whelan</surname><given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Remski</surname><given-names>K</given-names></string-name></person-group>. <article-title>Buprenorphine vs methadone treatment: a review of evidence in both developed and developing worlds</article-title>. <source>J Neurosci Rural Pract</source><year>2012</year>, <volume>3</volume>: <fpage>45</fpage>-<lpage>50</lpage>. doi: <pub-id pub-id-type="doi">10.4103/0976-3147.91934</pub-id>.<pub-id pub-id-type="pmid">22346191</pub-id><pub-id pub-id-type="pmcid">PMC3271614</pub-id></mixed-citation></ref><ref id="ref70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Marteau</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>McDonald</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Patel</surname><given-names>K</given-names></string-name></person-group>. <article-title>The relative risk of fatal poisoning by methadone or buprenorphine within the wider population of England and Wales</article-title>. <source>BMJ Open</source><year>2015</year>; <volume>5</volume>: <fpage>007629</fpage>. doi: <pub-id pub-id-type="doi">10.1136/bmj-open-2015-007629</pub-id>.<pub-id pub-id-type="pmcid">PMC4452747</pub-id><pub-id pub-id-type="pmid">26024998</pub-id></mixed-citation></ref><ref id="ref71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pinto</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Maskrey</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Swift</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Rumball</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Wagle</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Holland</surname><given-names>R</given-names></string-name></person-group>. <article-title>The SUMMIT trial: a field comparison of buprenorphine versus methadone maintenance treatment</article-title>. <source>J Subst Abuse Treat</source><year>2010</year>; <volume>39</volume>: <fpage>340</fpage>-<lpage>352</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jsat.2010.07.009</pub-id>.<pub-id pub-id-type="pmid">20817384</pub-id></mixed-citation></ref><ref id="ref72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jones</surname><given-names>HE</given-names></string-name>, <string-name name-style="western"><surname>Strain</surname><given-names>EC</given-names></string-name>, <string-name name-style="western"><surname>Bigelow</surname><given-names>GE</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Induction with levomethadyl acetate: safety and efficacy</article-title>. <source>Arch General Psychiatry</source><year>1998</year>; <volume>55</volume>: <fpage>729</fpage>-<lpage>736</lpage>. doi: <pub-id pub-id-type="doi">10.1001/archpsyc.55.8.729</pub-id>.<pub-id pub-id-type="pmid">9707384</pub-id></mixed-citation></ref><ref id="ref73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Clark</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Lintzeris</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Gijsbers</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>LAAM maintenance vs metha-done maintenance for heroin dependence</article-title>. <source>Cochrane Database Syst Rev</source><year>2002</year>; <volume>2</volume>: <fpage>CD002210</fpage>. doi: <pub-id pub-id-type="doi">10.1002/14651858.CD002210</pub-id>.<pub-id pub-id-type="pmid">12076441</pub-id></mixed-citation></ref><ref id="ref74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wieneke</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Conrads</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Wolstein</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Levo-&#945;-acetylmethadol (LAAM) induced QTc-prolongation-results from a controlled clinical trial</article-title>. <source>Eur J Med Res</source><year>2009</year>; <volume>14</volume>: <fpage>7</fpage>-<lpage>12</lpage>. doi: <pub-id pub-id-type="doi">10.1186/2047-783x-14-1-7</pub-id>.<pub-id pub-id-type="pmid">19258204</pub-id><pub-id pub-id-type="pmcid">PMC3352205</pub-id></mixed-citation></ref><ref id="ref75"><label>75</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>US Food and Drug Administration</collab></person-group>. <article-title>Product Discontinuation Notice. ORLAAM&#174; (Levomethadyl hydrochloride acetate) Oral Solution, 10 mg/mL, CII</article-title>. <year>2003</year>. <comment>Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.fda.gov/cder/drug/shortages/orlaam.htm" ext-link-type="uri">http://www.fda.gov/cder/drug/shortages/orlaam.htm</ext-link></comment>.</mixed-citation></ref><ref id="ref76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Johnson</surname><given-names>RE</given-names></string-name>, <string-name name-style="western"><surname>Chutuape</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Strain</surname><given-names>EC</given-names></string-name>, <string-name name-style="western"><surname>Walsh</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Stitzer</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Bigelow</surname><given-names>GE</given-names></string-name></person-group>. <article-title>A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence</article-title>. <source>N Engl J Med</source><year>2000</year>; <volume>343</volume>: <fpage>1290</fpage>-<lpage>1297</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJM200011023431802</pub-id>.<pub-id pub-id-type="pmid">11058673</pub-id></mixed-citation></ref><ref id="ref77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Anton</surname><given-names>RF</given-names></string-name></person-group>. <article-title>Naltrexone for the management of alcohol dependence</article-title>. <source>N Engl J Med</source><year>2008</year>; <volume>14</volume>: <fpage>715</fpage>-<lpage>721</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMct0801733</pub-id>.<pub-id pub-id-type="pmcid">PMC2565602</pub-id><pub-id pub-id-type="pmid">18703474</pub-id></mixed-citation></ref><ref id="ref78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rounsaville</surname><given-names>BJ</given-names></string-name></person-group>. <article-title>Can psychotherapy rescue naltrexone treatment of opioid addiction?</article-title><source>NIDA Res Monogr</source><year>1995</year>; <volume>150</volume>: <fpage>37</fpage>-<lpage>52</lpage>.<pub-id pub-id-type="pmid">8742771</pub-id></mixed-citation></ref><ref id="ref79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shah</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Stout</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Caskey</surname><given-names>H</given-names></string-name></person-group>. <article-title>Tramadol for the management of opioid withdrawal: a systematic review of randomized clinical trials</article-title>. <source>Cureus</source><year>2020</year>; <volume>12</volume>: <fpage>e9128</fpage>. doi: <pub-id pub-id-type="doi">10.7759/cureus.9128</pub-id>.<pub-id pub-id-type="pmid">32789069</pub-id><pub-id pub-id-type="pmcid">PMC7417126</pub-id></mixed-citation></ref><ref id="ref80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wheeler</surname><given-names>KE</given-names></string-name>, <string-name name-style="western"><surname>Grilli</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Centofanti</surname><given-names>JE</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Adjuvant analgesic use in the critically ill: a systematic review and meta-analysis</article-title>. <source>Crit Care Explor</source><year>2020</year>; <volume>2</volume>: <fpage>e0157</fpage>. doi: <pub-id pub-id-type="doi">10.1097/CCE.0000000000000157</pub-id>.<pub-id pub-id-type="pmid">32696016</pub-id><pub-id pub-id-type="pmcid">PMC7340332</pub-id></mixed-citation></ref><ref id="ref81"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Devlin</surname><given-names>JW</given-names></string-name>, <string-name name-style="western"><surname>Skrobik</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>G&#233;linas</surname><given-names>C</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU</article-title>. <source>Crit Care Med</source><year>2018</year>; <volume>46</volume>: <fpage>825</fpage>-<lpage>873</lpage>. doi: <pub-id pub-id-type="doi">10.1097/CCM.0000000000003299</pub-id>.<pub-id pub-id-type="pmid">30113379</pub-id></mixed-citation></ref><ref id="ref82"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Suzuki</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Eastwood</surname><given-names>GM</given-names></string-name>, <string-name name-style="western"><surname>Bailey</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Paracetamol therapy and outcome of critically ill patients: a multicenter retrospective observational study</article-title>. <source>Crit Care</source><year>2015</year>; <volume>19</volume>: <fpage>162</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13054-015-0865-1</pub-id>.<pub-id pub-id-type="pmid">25879463</pub-id><pub-id pub-id-type="pmcid">PMC4411740</pub-id></mixed-citation></ref><ref id="ref83"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kouchek</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mansouri</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Mokhtari</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Goharani</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Miri</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Sistani zad</surname><given-names>M</given-names></string-name></person-group>. <article-title>A comparative study of intravenous paracetamol and fentanyl for pain management in ICU</article-title>. <source>Iran J Pharm Res</source><year>2013</year>; <volume>12</volume>: <fpage>193</fpage>-<lpage>198</lpage>.<pub-id pub-id-type="pmcid">PMC3813193</pub-id><pub-id pub-id-type="pmid">24250588</pub-id></mixed-citation></ref><ref id="ref84"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Narayanan</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Venkataraju</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Jennings</surname><given-names>J</given-names></string-name></person-group>. <article-title>Analgesia in intensive care: part 1</article-title>. <source>Baja Education</source><year>2016</year>; <volume>16</volume>: <fpage>72</fpage>-<lpage>78</lpage>. doi: <pub-id pub-id-type="doi">10.1093/bjaceaccp/mkv018</pub-id>.</mixed-citation></ref><ref id="ref85"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Guillou</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Tanguy</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Seguin</surname><given-names>P</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The effects of small-dose ketamine on morphine consumption in surgical intensive care unit patients after major abdominal surgery</article-title>. <source>Anesth Analg</source><year>2003</year>; <volume>97</volume>: <fpage>843</fpage>-<lpage>847</lpage>. doi: <pub-id pub-id-type="doi">10.1213/01.ANE.0000075837.67275.36</pub-id>.<pub-id pub-id-type="pmid">12933413</pub-id></mixed-citation></ref><ref id="ref86"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Washton</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Resnick</surname><given-names>RB</given-names></string-name></person-group>. <article-title>Clonidine in opiate withdrawal: review and appraisal of clinical findings</article-title>. <source>Pharmacotherapy</source><year>1981</year>; <volume>10</volume>: <fpage>140</fpage>-<lpage>146</lpage>. doi: <pub-id pub-id-type="doi">10.1002/j.1875-9114.1981.tb03561.x</pub-id>.<pub-id pub-id-type="pmid">6765486</pub-id></mixed-citation></ref><ref id="ref87"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Beswick</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Best</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Bearn</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gossop</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rees</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Strang</surname><given-names>J</given-names></string-name></person-group>. <article-title>The effectiveness of combined naloxone/lofexidine in opiate detoxification: results from a double-blind randomized and placebo-controlled trial</article-title>. <source>Am J Addict</source><year>2003</year>; <volume>12</volume>: <fpage>295</fpage>-<lpage>305</lpage>.<pub-id pub-id-type="pmid">14504022</pub-id></mixed-citation></ref><ref id="ref88"><label>88</label><mixed-citation publication-type="book"><article-title>Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence</article-title>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name>; <year>2009</year>.<pub-id pub-id-type="pmid">23762965</pub-id></mixed-citation></ref><ref id="ref89"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Connery</surname><given-names>HS</given-names></string-name></person-group>. <article-title>Medication-assisted treatment of opioid use disorder: review of the evidence and future directions</article-title>. <source>Harv Rev Psychiatry</source><year>2015</year>; <volume>23</volume>: <fpage>63</fpage>-<lpage>75</lpage>. doi: <pub-id pub-id-type="doi">10.1097/HRP.0000000000000075</pub-id>.<pub-id pub-id-type="pmid">25747920</pub-id></mixed-citation></ref><ref id="ref90"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dugosh</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Abraham</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Seymour</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>McLoyd</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Chalk</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Festinger</surname><given-names>D</given-names></string-name></person-group>. <article-title>A systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of opioid addiction</article-title>. <source>J Addict Med</source><year>2016</year>; <volume>10</volume>: <fpage>93</fpage>-<lpage>103</lpage>. doi: <pub-id pub-id-type="doi">10.1097/ADM.0000000000000193</pub-id>.<pub-id pub-id-type="pmid">26808307</pub-id><pub-id pub-id-type="pmcid">PMC4795974</pub-id></mixed-citation></ref><ref id="ref91"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Karamchandani</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Carr</surname><given-names>ZJ</given-names></string-name>, <string-name name-style="western"><surname>Bonavia</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Tung</surname><given-names>A</given-names></string-name></person-group>. <article-title>Critical care pain management in patients affected by the opioid epidemic: a review</article-title>. <source>Ann Am Thorac Soc</source><year>2018</year>; <volume>15</volume>: <fpage>1016</fpage>-<lpage>1023</lpage>. doi: <pub-id pub-id-type="doi">10.1513/AnnalsATS.201801-028FR</pub-id>.<pub-id pub-id-type="pmid">29812953</pub-id></mixed-citation></ref><ref id="ref92"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>PP</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Feng</surname><given-names>X</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Opioid-associated iatrogenic withdrawal in critically ill adult patients: a multicenter prospective observational study</article-title>. <source>Ann Intensive Care</source><year>2017</year>; <volume>7</volume>: <fpage>88</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13613-017-0310-5</pub-id>.<pub-id pub-id-type="pmid">28866754</pub-id><pub-id pub-id-type="pmcid">PMC5581799</pub-id></mixed-citation></ref><ref id="ref93"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hyun</surname><given-names>DG</given-names></string-name>, <string-name name-style="western"><surname>Huh</surname><given-names>JW</given-names></string-name>, <string-name name-style="western"><surname>Hong</surname><given-names>SB</given-names></string-name>, <string-name name-style="western"><surname>Koh</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Lim</surname><given-names>CM</given-names></string-name></person-group>. <article-title>Iatrogenic opioid withdrawal syndrome in critically ill patients: a retrospective cohort study</article-title>. <source>J Korean Med Sci</source><year>2020</year>; <volume>35</volume>: <fpage>e106</fpage>. doi: <pub-id pub-id-type="doi">10.3346/jkms.2020.35.e106</pub-id>.<pub-id pub-id-type="pmid">32301295</pub-id><pub-id pub-id-type="pmcid">PMC7167401</pub-id></mixed-citation></ref><ref id="ref94"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ehieli</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Yalamuri</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Brudney</surname><given-names>CS</given-names></string-name>, <string-name name-style="western"><surname>Pyati</surname><given-names>S</given-names></string-name></person-group>. <article-title>Analgesia in the surgical intensive care unit</article-title>. <source>Postgrad Med J</source><year>2017</year>; <volume>93</volume>: <fpage>38</fpage>-<lpage>45</lpage>. doi: <pub-id pub-id-type="doi">10.1136/postgradmedj-2016-134047</pub-id>.<pub-id pub-id-type="pmid">27777355</pub-id></mixed-citation></ref><ref id="ref95"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gowing</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Ali</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>White</surname><given-names>JM</given-names></string-name></person-group>. <article-title>Buprenorphine for the management of opioid withdrawal</article-title>. <source>Cochrane Database Syst Rev</source><year>2009</year>; <volume>3</volume>: <fpage>CD002025</fpage>. doi: <pub-id pub-id-type="doi">10.1002/14651858.CD002025</pub-id>.<pub-id pub-id-type="pmid">19588330</pub-id></mixed-citation></ref><ref id="ref96"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Das</surname><given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Sharma</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kothari</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Goyal</surname><given-names>S</given-names></string-name></person-group>. <article-title>Opium addiction: practical issues in ICU</article-title>. <source>Indian J Crit Care Med</source><year>2021</year>; <volume>25</volume>: <fpage>1082</fpage>-<lpage>1083</lpage>. doi: <pub-id pub-id-type="doi">10.5005/jp-journals-10071-23939</pub-id>.<pub-id pub-id-type="pmid">34963736</pub-id><pub-id pub-id-type="pmcid">PMC8664020</pub-id></mixed-citation></ref><ref id="ref97"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Baumbach</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>G&#246;tz</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>G&#252;nther</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Weiss</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Meissner</surname><given-names>W</given-names></string-name></person-group>. <article-title>Somatosensory functions in survivors of critical illness</article-title>. <source>Crit Care Med</source><year>2017</year>; <volume>45</volume>: <fpage>e567</fpage>-<lpage>e574</lpage>. doi: <pub-id pub-id-type="doi">10.1097/CCM.0000000000002309</pub-id>.<pub-id pub-id-type="pmid">28328653</pub-id></mixed-citation></ref><ref id="ref98"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>M&#228;kinen</surname><given-names>OJ</given-names></string-name>, <string-name name-style="western"><surname>B&#228;cklund</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Liisanantti</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Peltomaa</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Karlsson</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kalliom&#228;ki</surname><given-names>ML</given-names></string-name></person-group>. <article-title>Persistent pain in intensive care survivors: a systematic review</article-title>. <source>Br J Anaesth</source><year>2020</year>; <volume>125</volume>: <fpage>149</fpage>-<lpage>158</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bja.2020.04.084</pub-id>.<pub-id pub-id-type="pmid">32564888</pub-id></mixed-citation></ref><ref id="ref99"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Doerr</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Chidgey</surname><given-names>B</given-names></string-name></person-group>. <article-title>Should surgeons or anesthesiologists manage perioperative pain protocols?</article-title><source>AMA J Ethics</source><year>2020</year>; <volume>22</volume>: <fpage>E319</fpage>-<lpage>324</lpage>. doi: <pub-id pub-id-type="doi">10.1001/amajethics.2020.319</pub-id>.<pub-id pub-id-type="pmid">32345425</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>